Making the most of one's investment time in the stock market and doing it with self-assurance are common objectives for both novice and seasoned investors.
The Zacks Style Scores are a one-of-a-kind set of rules for evaluating companies according to three widely used investing methodologies: growth, momentum, and value. They make it easier to achieve these goals. With the Style Scores, you can more easily determine which stocks are better suited to your portfolio and have a greater chance of outperforming the market in the long run. Is This One Momentum Stock an Absolute Must-Have Right Now?
Value investors seek out inexpensive but high-quality equities and look for firms that are trading at a discount to their actual worth. Accordingly, in order to identify the best bargain companies, the Value Style Score considers ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow.
Located in Boulder, CO With a focus on cancer and other high-burden illnesses, Array BioPharma is a biopharmaceutical business that discovers, develops, and commercializes targeted small molecule medications. Braftovi (encorafenib) with Mektovi (binimetinib) is the only marketed combination medication in the company's portfolio
If your melanoma has a BRAF V600E or V600K mutation and is either unresectable or has spread, this treatment may be able to help. For the combo treatment, the business is also doing label expansion trials
ARRY is a company that has a Value Style Score of A and a VGM Score of A. It is ranked #3 (Hold) by Zacks. Array Technologies, Inc.'s stock is selling at a forward P/E of 10.9X, which is lower than the solar industry average. In addition to these metrics, ARRY's PEG Ratio is 0.2, its Price/Cash Flow is 10.2X, and its Price/Sales is 1.3X.
Additionally, a company's results are closely monitored by many value investors. The Zacks Consensus Estimate for ARRY's 2023 profits has risen $0.01 to $1.03 per share, as four analysts have raised their earnings estimates in the past 60 days. On average, ARRY's profits surprised investors by 245.7% per share.
Investors should seriously consider adding ARRY to their portfolios because to its great valuation and earnings figures, good Zacks Rank, and top-tier Value and VGM Style Scores.
STAY TURNED FOR DEVELOPMENT